Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

NCT00462189 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Hairy Cell Leukemia
HCL

Interventions

DRUG: Immunotoxin therapy
DRUG: CAT-8015 Immunotoxin
PROCEDURE: Biological therapy

Sponsor

Cambridge Antibody Technology